TGFB1 and neoplasm: Cancer cells release TGF-β that activates CAF, which then secretes various immunomodulatory chemicals, including IL-11, IL-6, and TGF-β, to not only inhibit anti-tumor immunity but also deposit increasing amounts of ECM (30, 31).